Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "GRIN-Therapeutics"

2 News Found

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
Clinical Trials | January 14, 2026

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
News | July 10, 2024

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies

Latest Stories

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM

ISVIR 2026 showcases cutting-edge interventional radiology in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging